Genmab enters collaboration with US firm Biolex Therapeutics  

2007.05.21
Danish biotech firm Genmab will evaluate Biolex’s LEX System as a potential manufacturing platform for antibodies developed with Genmab’s proprietary antibody technology
Danish biotech firm Genmab has signed a cooperation agreement with US company Biolex Therapeutics. Under the agreement Genmab will evaluate Biolex’s LEX System as a potential manufacturing platform for antibodies developed with UniBody, Genmab’s proprietary antibody technology.

Jan Turek, president and CEO of Biolex commented: "We are excited to be working with Genmab, as their UniBody technology represents a major potential advancement in the antibody space and gives us the opportunity to further leverage our unique approach to protein production."
 
Biolex Therapeutics is a venture capital-backed company located in the Research Triangle region of North Carolina. The company develops and commercialises therapeutic proteins based on its patented expression system that enables the production of hard-to-make proteins and the optimization of monoclonal antibodies. Biolex's lead clinical candidate is a controlled-release treatment for hepatitis C.
 
Genmab A/S creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. The company has a portfolio of products in development to treat cancer, rheumatoid arthritis, infectious diseases and other inflammatory conditions.
 
Link > Genmab   

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×